AC302 was a successful pivotal Phase 3 trial across all three co-primary endpoints
Consistent results across AC301 and AC302 for two of three co-primary endpoints
Positive B-SIMPLE4 results validated our technology and our effective trial execution
We believe among dermatology health-care providers there remains a significant unmet need for novel mechanisms of action with favorable tolerability profiles to improve patient outcomes in acne.
acne in the U.S.1
Topical U.S. acne market (products
Acne has significant physical and psychological morbidity, such as permanent scarring, poor self-image, depression and anxiety
- Bickers DR, Lim HW, Margolis D, Weinstock MA, Goodman C, Faulkner E et al. The burden of skin diseases: 2004 a joint project of the American Academy of Dermatology Association and the Society for Investigative Dermatology. Journal of the American Academy of Dermatology 2006;55:490-500.
- IMS National Prescription Audit MAT Feb. 2016 – Acne Prescription Market TRx Dollars – MAT Feb 2016